HC Wainwright restated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $4.00 target price on the biopharmaceutical company’s stock. LXRX has been the topic of a number of other reports. Wall Street Zen assumed coverage on […]

HC Wainwright reaffirmed their buy rating on shares of Redwire (NYSE:RDW – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $26.00 price objective on the stock. HC Wainwright also issued estimates for Redwire’s Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at $0.05 EPS and FY2026 earnings at […]

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) was upgraded by equities researchers at HC Wainwright to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports. Separately, Canaccord Genuity Group started coverage on Eupraxia Pharmaceuticals in a report on Monday, June 16th. They set a “speculative buy” rating for the company. Three investment analysts […]